Last reviewed · How we verify

IV Aminophylline — Competitive Intelligence Brief

IV Aminophylline (IV Aminophylline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Xanthine bronchodilator. Area: Respiratory.

marketed Xanthine bronchodilator Phosphodiesterase; adenosine receptors Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

IV Aminophylline (IV Aminophylline) — Damanhour Teaching Hospital. Aminophylline is a xanthine derivative that inhibits phosphodiesterase enzymes and blocks adenosine receptors, leading to increased intracellular cAMP and bronchodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IV Aminophylline TARGET IV Aminophylline Damanhour Teaching Hospital marketed Xanthine bronchodilator Phosphodiesterase; adenosine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Xanthine bronchodilator class)

  1. Damanhour Teaching Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV Aminophylline — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-aminophylline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: